These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26342406)

  • 1. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Gorodnova TV; Sokolenko AP; Ivantsov AO; Iyevleva AG; Suspitsin EN; Aleksakhina SN; Yanus GA; Togo AV; Maximov SY; Imyanitov EN
    Cancer Lett; 2015 Dec; 369(2):363-7. PubMed ID: 26342406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
    Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    Sokolenko AP; Bizin IV; Preobrazhenskaya EV; Gorodnova TV; Ivantsov AO; Iyevleva AG; Savonevich EL; Kotiv KB; Kuligina ES; Imyanitov EN
    Int J Cancer; 2020 Apr; 146(7):1879-1888. PubMed ID: 31693165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
    Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
    Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
    Sokolenko A; Preobrazhenskaya E; Marchetti C; Piermattei A; Zagrebin F; Kuligina E; Gorodnova T; Pavone M; Ivantsov A; Bizin I; Scambia G; Berlev I; Fagotti A; Imyanitov E
    Pathobiology; 2024; 91(2):108-113. PubMed ID: 37579727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
    King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
    Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
    Safra T; Rogowski O; Muggia FM
    Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.
    Rodríguez AO; Llacuachaqui M; Pardo GG; Royer R; Larson G; Weitzel JN; Narod SA
    Gynecol Oncol; 2012 Feb; 124(2):236-43. PubMed ID: 22044689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
    Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
    Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
    Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
    Ginolhac SM; Gad S; Corbex M; Bressac-De-Paillerets B; Chompret A; Bignon YJ; Peyrat JP; Fournier J; Lasset C; Giraud S; Muller D; Fricker JP; Hardouin A; Berthet P; Maugard C; Nogues C; Lidereau R; Longy M; Olschwang S; Toulas C; Guimbaud R; Yannoukakos D; Szabo C; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Goldgar D; Stoppa-Lyonnet D; Lenoir GM; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):90-5. PubMed ID: 12582017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.